

REVIEW ARTICLE

Efficacy and safety of brexpiprazole for agitation in Alzheimer's disease: A systematic review and meta-analysis

Supplementary Files

Search strategy:

Search strategy for identifying studies on brexpiprazole for agitation in Alzheimer's disease. A comprehensive and systematic literature search was conducted in the following databases:

- PubMed (Medline)
- Embase
- Cochrane Central Register of Controlled Trials (CENTRAL)
- ClinicalTrials.gov

Search strings

(a) PubMed (Medline) search string

("Alzheimer's disease" [MeSH] OR "Alzheimer's dementia" OR "Alzheimer" OR "dementia") AND

("agitation" [MeSH] OR "behavioral symptoms" OR "aggressive behavior" OR "neuropsychiatric symptoms")

AND

("brexpiprazole"[MeSH] OR "OPC-34712" OR "serotonin-dopamine activity modulator") AND

("Randomized Controlled Trial" [publication type] OR "RCT" OR "randomized trial" OR "clinical trial")

(b) Embase search string

("Alzheimer's disease"/exp OR "Alzheimer's dementia" OR "Alzheimer" OR "dementia") AND

("agitation"/exp OR "behavioral symptoms" OR "aggressive behavior" OR "neuropsychiatric

symptoms") AND

("brexpiprazole"/exp OR "OPC-34712" OR "serotonin-dopamine activity modulator") AND

("randomized controlled trial"/exp OR "RCT" OR "randomized trial" OR "clinical trial")

(c) Cochrane CENTRAL search string

(Alzheimer's disease) OR (Alzheimer's dementia) OR (Alzheimer) OR (dementia) AND

(agitation) OR (behavioral symptoms) OR (aggressive behavior) OR (neuropsychiatric symptoms) AND

(brexpiprazole) OR (OPC-34712) OR (serotonin-dopamine activity modulator) AND

(randomized controlled trial) OR (RCT) OR (randomized trial) OR (clinical trial)

(d) ClinicalTrials.gov search strategy

- Condition/Disease: Alzheimer's disease, agitation
- Intervention: Brexpiprazole
- Study Type: Interventional (clinical trials)
- Phase: All phases
- Status: Completed, recruiting, active, not yet recruiting
- Filters applied: Randomized

(e) Additional search methods

- The reference lists of included studies and relevant systematic reviews were screened for additional eligible trials.
- Gray literature, including conference abstracts and unpublished studies, was reviewed where available.




Figure S1. Funnel plot of comparison for outcome: Change in Cohen–Mansfield Agitation Inventory score at week 10–12 from baseline. Note: SE (MD): Standard error of the mean difference.
Abbreviation: MD: Mean difference.




Figure S2. Funnel plot of comparison for outcome: Change in Clinical Global Impressions-Severity score as related to agitation at week 10–12 from baseline. Note: SE (MD): Standard error of the mean difference.
Abbreviation: MD: Mean difference.




Figure S3. Funnel plot of comparison for outcome: Change in Neuropsychiatric Inventory-Nursing Home score at week 10–12 from baseline.
 Note: SE (MD): Standard error of the mean difference.
 Abbreviation: MD: Mean difference.




Figure S4. Funnel plot of comparison for the outcome of adverse events that emerged during treatment.
 Abbreviations: RR: Risk ratio; SE: Standard error.




Figure S5. Funnel plot for the outcome of treatment discontinuation due to treatment-emergent adverse event.
Abbreviations: RR: Risk ratio; SE: Standard error.